GlassScriptPhysician profile
Dennis J Nave
NPI 1396761763
$5,614.99
in general payments reported to CMS, 2019-2025
32 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $370 · 2021: $11.61 · 2022: $189 · 2023: $1,082 · 2024: $1,105 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,779.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $613.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $449.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $431.40 | 2019-2025 | |
| Abbvie INC. | $373.73 | 2019-2025 | |
| Glaxosmithkline, LLC. | $368.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.94 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $324.13 | 2022-2025 | |
| Astellas Pharma US INC | $306.25 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $299.38 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $235.35 | 2019-2024 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $231.23 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $193.28 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Amarin Pharma, INC. | $144.52 | 2019-2023 | |
| Abbott Laboratories | $140.87 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $116.02 | 2019-2024 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $104.10 | 2019-2025 | |
| Lundbeck LLC | $98.43 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $87.63 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $85.05 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.71 | 2025 | Caplyta |
| Exact Sciences Corporation | $74.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.48 | 2019-2023 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $68.19 | 2024-2025 | Voquezna |
| Treace Medical Concepts, INC. | $67.57 | 2024 | |
| Allergan, INC. | $63.32 | 2019-2020 | |
| Axsome Therapeutics, INC. | $55.99 | 2025 | Auvelity |
| Grifols USA, LLC | $54.48 | 2019-2020 | |
| Genentech USA, INC. | $38.79 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $26.98 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.51 | 2019 | |
| Inspire Medical Systems, INC. | $23.77 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $23.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Nave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.